Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 1/20 | 0.40 |
| ▸ | MTNR1A | P48039 | 10/20 | 0.38 |
| ▸ | MTNR1B | P49286 | 10/20 | 0.38 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.38 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.38 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 2/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.34 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | APP | P05067 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29568322 | 0.78 | CHRNB2 (0.44) | ADRA2AADRA2BADRA2CTSHRCYP3A4 | |
| SCHEMBL359803 | 0.78 | CHRNB2 (0.44) | ADRA2AADRA2BADRA2CTSHRCYP3A4 | |
| SCHEMBL14395237 | 0.78 | CHRNB2 (0.44) | ADRA2AADRA2BADRA2CTSHRCYP3A4 | |
| Hydrochloric Acid SCHEMBL27585427 | 0.76 | MAPT (0.44) | ADRA2AADRA2BADRA2CTSHRCYP3A4 | |
| Bromide SCHEMBL3966126 | 0.76 | CHRNB2 (0.42) | ADRA2AADRA2BADRA2CTSHRCYP3A4 | |
| SCHEMBL24329565 | 0.76 | PNMT (0.33) | CYP1A2 | |
| SCHEMBL10802574 | 0.72 | MTNR1A (0.39) | PARP1MTNR1AMTNR1BADRA2AADRA2B | |
| SCHEMBL3069045 | 0.71 | PARP1 (0.38) | PARP1MTNR1AMTNR1BADRA2AADRA2B | |
| SCHEMBL16213289 | 0.71 | MEN1 (0.40) | PARP1TSHRCYP3A4HSD17B10MEN1 | |
| SCHEMBL7883274 | 0.71 | MTNR1A (0.47) | MTNR1AMTNR1BADRA2AADRA2BADRA2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10011714-B2 | Monolayer carbon dioxide barrier PET bottles | PLASTIPAK PACKAGING, INC. (US) | 2018-07-03 | — | — | US | disclosed |
| US-20170290820-A1 | METHODS AND COMPOSITIONS FOR TREATING BETA-THALASSEMIA AND SICKLE CELL DISEASE | ACADEMIA SINICA (TW) | 2017-10-12 | — | — | US | disclosed |
| US-9662324-B2 | Methods and compositions for treating β-thalassemia and sickle cell disease | ACADEMIA SINICA (TW) | 2017-05-30 | — | — | US | disclosed |
| US-9662324-B2 | Methods and compositions for treating β-thalassemia and sickle cell disease | ACADEMIA SINICA (TW) | 2017-05-30 | — | — | US | disclosed |
| US-9662324-B2 | Methods and compositions for treating β-thalassemia and sickle cell disease | ACADEMIA SINICA (TW) | 2017-05-30 | — | — | US | disclosed |
| US-20160106728-A1 | METHODS AND COMPOSITIONS FOR TREATING BETA-THALASSEMIA AND SICKLE CELL DISEASE | ACADEMIA SINICA (TW) | 2016-04-21 | — | — | US | disclosed |
| US-20160106728-A1 | METHODS AND COMPOSITIONS FOR TREATING BETA-THALASSEMIA AND SICKLE CELL DISEASE | ACADEMIA SINICA (TW) | 2016-04-21 | — | — | US | disclosed |
| US-20160106728-A1 | METHODS AND COMPOSITIONS FOR TREATING BETA-THALASSEMIA AND SICKLE CELL DISEASE | ACADEMIA SINICA (TW) | 2016-04-21 | — | — | US | disclosed |
| WO-2014179567-A2 | METHODS AND COMPOSITIONS FOR TREATING BETA-THALASSEMIA AND SICKLE CELL DISEASE | ACADEMIA SINICA (TW) | 2014-11-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170290820-A1 | METHODS AND COMPOSITIONS FOR TREATING BETA-THALASSEMIA AND SICKLE CELL DISEASE | HBB, HBZ, HBG1 | PARP1 3307/4885MTNR1A 4410/4885MTNR1B 3397/4885 |
| US-20160106728-A1 | METHODS AND COMPOSITIONS FOR TREATING BETA-THALASSEMIA AND SICKLE CELL DISEASE | HBB, HBZ, HBG1 | PARP1 3307/4885MTNR1A 4410/4885MTNR1B 3397/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.